참고문헌
- Belani CP, Barstis J, Perry MC, et al (2003). Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol, 21, 2933-9. https://doi.org/10.1200/JCO.2003.02.563
- Belani CP, Pereira JR, von Pawel J, et al (2006). Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life. A randomized controlled trial. Lung Cancer, 53, 231-9. https://doi.org/10.1016/j.lungcan.2006.05.003
- Brodowicz T, Krzakowski M, Zwitter M, et al (2006). Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial. Lung Cancer, 52, 55-63.
- Cappuzzo F, Ciuleanu L, Stelmakh S, et al (2010). Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised,placebo-controlled phase 3 study. Lancet Oncol, 11, 521-9. https://doi.org/10.1016/S1470-2045(10)70112-1
- Cella DF, Tulsky DS, Gray G, et al (1993). The functional assessment of cancer therapy scale. Development and validation of the general measure. J Clin Oncol, 11, 570-9. https://doi.org/10.1200/JCO.1993.11.3.570
- Chiappori A, Simon G, Williams C, et al (2005). Phase II study of first-line sequential chemotherapy with gemcitabinecarboplatin followed by docetaxel in patients with advanced non-small cell lung cancer. Oncology, 68, 382-90. https://doi.org/10.1159/000086979
- Ciuleanu T, Brodowicz T, Zielinski C, et al (2007). Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet, 374, 1432-40.
- Edelman MJ, Clark JI, Chansky K, et al (2004). Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): Carboplatin/ gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel. Clin Cancer Res, 10, 5022-6. https://doi.org/10.1158/1078-0432.CCR-04-0002
- Fidias PM, Dakhil SR, Lyss AP, et al (2009). Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced nonsmall- cell lung cancer. J Clin Oncol, 27, 591-8. https://doi.org/10.1200/JCO.2008.17.1405
- Fisher MD, D'Orazio A (2000). Phase II and III trials: comparison of four chemotherapy regimens in advanced non small-cell lung cancer (ECOG 1594). Clin Lung Cancer, 2, 21-2. https://doi.org/10.1016/S1525-7304(11)70620-9
- Grossi F, Aita M, Follador A, et al (2007). Sequential, alternating, and maintenance/consolidation chemotherapy in advanced non-small cell lung cancer: a review of the literature. Oncologist, 12, 451-64. https://doi.org/10.1634/theoncologist.12-4-451
- Grossi F, Belvedere O, Fasola G, et al (2004). Sequential chemotherapy with paclitaxel plus cisplatin, followed by vinorelbine, followed by gemcitabine in advanced onsmall cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 001). Lung Cancer, 46, 99-106. https://doi.org/10.1016/j.lungcan.2004.03.003
- Hosoe S, Komuta K, Shibata K, et al (2003). Gemcitabine and vinorelbine followed by docetaxel in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial of nonplatinum sequential triplet combination chemotherapy (JMTO LC00-02). Br J Cancer, 88, 342-7. https://doi.org/10.1038/sj.bjc.6600723
- Non-small Cell Lung Cancer Collaborative Group (1995). Chemotherapy in non-small cell lung cancer: a metaanalysis using updated data on individual patients from 52 randomized clinical trials. BMJ, 311, 899-90. https://doi.org/10.1136/bmj.311.7010.899
- Pallis A, Agelidou A, Papakotoulas P, et al (2006). A multicenter phase II study of sequential vinorelbine and cisplatin followed by docetaxel and gemcitabine in patients with advanced non-small cell lung cancer. Lung Cancer, 52, 165-71. https://doi.org/10.1016/j.lungcan.2006.01.005
- Schiller JH, Harrington D, Belani CP, et al (2002). Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med, 346, 92-8. https://doi.org/10.1056/NEJMoa011954
- Smith IE, O'Brien ME, Talbot DC, et al (2001). Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol, 19, 1336-43. https://doi.org/10.1200/JCO.2001.19.5.1336
- Socinski MA, Schell MJ, Peterman A, et al (2002). Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol, 20, 1335-43. https://doi.org/10.1200/JCO.20.5.1335
- Westeel V, Quoix E, Moro-Sibilot D, et al (2005). Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer. J Natl Cancer Inst, 97, 499-506. https://doi.org/10.1093/jnci/dji096
피인용 문헌
- Phase II Study on Dose Escalating Schedule of Paclitaxel Concurrent with Radiotherapy in Treating Patients with Locally Advanced Non-small Cell Lung Cancer vol.15, pp.4, 2014, https://doi.org/10.7314/APJCP.2014.15.4.1699
- Clinical Efficacy of Bevacizumab Concomitant with Pemetrexed in Patients with Advanced Non-small Cell Lung Cancer vol.15, pp.8, 2014, https://doi.org/10.7314/APJCP.2014.15.8.3447
- Association between polymorphisms of BAG-1 and XPD and chemotherapy sensitivity in advanced non-small-cell lung cancer patients treated with vinorelbine combined cisplatin regimen vol.36, pp.12, 2015, https://doi.org/10.1007/s13277-015-3672-z
- Changes to and Determinants of Quality of Life in Patients With Advanced Non-Small-Cell Lung Cancer Undergoing Initial Chemotherapy pp.1682-3141, 2017, https://doi.org/10.1097/jnr.0000000000000148
- microRNA-664 enhances proliferation, migration and invasion of lung cancer cells vol.13, pp.6, 2017, https://doi.org/10.3892/etm.2017.4433
- The Cdc2/Cdk1 inhibitor, purvalanol A, enhances the cytotoxic effects of taxol through Op18/stathmin in non-small cell lung cancer cells in vitro vol.40, pp.1, 2017, https://doi.org/10.3892/ijmm.2017.2989
- Op18/Stathmin Is Involved in the Resistance of Taxol Among Different Epithelial Carcinoma Cell Lines vol.29, pp.9, 2014, https://doi.org/10.1089/cbr.2014.1649